अApnaFunda
Menu

GLAXOSMITHKLINE PHARMACEUTICAL (GLAXO)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.81 / 100
Profitability 95Growth 49Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.57 / 100
Price 74Earnings 43FII/DII 54

Passes these screensQuality CompounderDebt-light & profitableInstitutions in, retail out

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹2,710 latest close · +13.1% over the last 90 sessions

₹2,500₹2,750₹3,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹2,500₹2,750₹3,000Jul 3Sep 4Nov 9

₹2,710 month-end · +8.2% over 12 months

₹2,500₹3,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹2,500₹3,000Nov '25May '26Nov '26

₹2,710 month-end · +67.7% over 3 years

₹2,000₹3,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹2,000₹3,000Nov '23May '25Nov '26

₹2,710 month-end · +97.2% since Jan '19

₹1,000₹2,000₹3,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹1,000₹2,000₹3,000Jan '19Dec '22Nov '26

52-week range ₹2088.10 to ₹3120.70 · 1-year volatility 26.7%

Was the rally earned?

+8%share price, 1 yearLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 12 points, but investors now pay less per rupee of profit (P/E 44.7x to 43.0x), which took 4 points back.
  • The share count barely moved.
Net profit growth: +12 pts. Points of the price return explained by net profit growing (or shrinking).+12 ptsNet profit growthP/E change: −4 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−4 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +8%+8%Share priceNet profit growth: +12 pts. Points of the price return explained by net profit growing (or shrinking).+12ProfitP/E change: −4 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−4P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +8%+8%Share price
Net profit growth+12 ptsNet profit rose about 12%, which lifts the price.
P/E change-4 ptsThe P/E fell from 44.7x to 43.0x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+68%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 73 points, but investors now pay less per rupee of profit (P/E 44.8x to 43.0x), which took 5 points back.
  • The share count barely moved.
Net profit growth: +73 pts. Points of the price return explained by net profit growing (or shrinking).+73 ptsNet profit growthP/E change: −5 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−5 ptsP/E changeShare price: +68%+68%Share priceNet profit growth: +73 pts. Points of the price return explained by net profit growing (or shrinking).+73ProfitP/E change: −5 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−5P/EShare price: +68%+68%Share price
Net profit growth+73 ptsNet profit rose about 75%, which lifts the price.
P/E change-5 ptsThe P/E fell from 44.8x to 43.0x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+66%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 142 points, but investors now pay less per rupee of profit (P/E 77.5x to 43.0x), which took 77 points back.
  • The share count barely moved.
Net profit growth: +142 pts. Points of the price return explained by net profit growing (or shrinking).+142 ptsNet profit growthP/E change: −77 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−77 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +66%+66%Share priceNet profit growth: +142 pts. Points of the price return explained by net profit growing (or shrinking).+142ProfitP/E change: −77 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−77P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +66%+66%Share price
Net profit growth+142 ptsNet profit rose about 198%, which lifts the price.
P/E change-77 ptsThe P/E fell from 77.5x to 43.0x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-37.8%not yet recovered
1-year volatility26.7%annualised
Beta vs sector index0.933-year daily, correlation 0.40
Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−37.2% 0%−20%−40%2020202220242026−37.2%
Largest drawdowns

-37.8% (2025-06 peak to 2026-06 low, not yet recovered)

-36.1% (2024-08 peak to 2025-02 low, recovered 2025-05)

-35.1% (2019-11 peak to 2020-03 low, recovered 2020-09)

Most recent volume spikes

2026-11-09: 16.3x the 50-day median, price +6.7% that day

2026-09-28: 7.2x the 50-day median, price +2.9% that day

2026-08-19: 16.5x the 50-day median, price +5.4% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

43.0xP/E todayWithin its usual range
Against its own history26th percentile
CheapestMedian 56.3xDearest

Usual range 14.0x to 257.4x since 2019-01.

Against Health Technology43.0x vs 37.0x
This company
43.0x
Sector median
37.0x

16% above the Health Technology median.

12.1x104.0x196.0x287.9xJan '19Aug '20Mar '22Oct '23May '25Nov '2612.1x104.0x196.0x287.9xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE99thflat vs a year ago
  • Op. margin91stflat vs a year ago
  • Revenue growth30th▼ 14 pts vs a year ago
  • EPS growth57th▼ 28 pts vs a year ago
  • Debt/equity ↓89th▼ 4 pts vs a year ago
  • Cash cycle ↓95thflat vs a year ago
  • P/E ↓39th▲ 7 pts vs a year ago
  • 12M momentum51st▼ 28 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~22%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 47.2x, a holder earning 12%/yr needs earnings to grow about 21.6%/yr for 10 years, then trade at 15x.

Delivered12.3%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+9.3 ptsimplied minus delivered
Rank344thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-9%11%31% Jan 2019Nov 2026 -9%11%31% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x22.7%23.8%24.9%
15x20.6%21.6%22.7%
20x17.7%18.8%19.8%

Drag a slider to test other assumptions

Implied: 21.6%/yr

Looking back

  • Jan 2020Price implied 27%/yr; EPS has since grown 13%/yr (7.0 yrs)
  • Jan 2021Price implied 28%/yr; EPS has since grown 50%/yr (6.0 yrs)
  • Jan 2022Price implied 29%/yr; EPS has since grown 24%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹2710.00
P/E
43.0x
ROCE
61.0%
Market Cap
₹45915 cr
Revenue (TTM)
₹3954 cr
P/S
11.6x
P/B
20.3x
ROE
47.1%
Operating Margin
31.0%
Debt / Equity
0.0x
Promoter Holding
75.0%
12M Momentum
8.2%

52-week range

₹2088.10₹3120.70
60% of the way from its 52-week low to its high

Price risk

1Y volatility
26.7%
Beta vs sector
1-year daily
0.68

Balance sheet & cash

Interest cover
operating profit ÷ interest
100.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.09x
Share count, 1Y
unchanged

Are profits backed by cash?

7 of 7checks within rangeAll clear
Other income reliance11%Within range

Other income as a share of pre-tax profit (trailing twelve months): 11.5%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate27%Within range

Median quarterly effective tax rate over about 2.5 years: 27.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.09xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.09x (cash from operations ₹2,775 cr, net profit ₹2,554 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+3 daysWithin range

Debtor days are above the median of the previous three fiscal years by 3 days (26 vs 23). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress12% of fixed assetsWithin range

Capital work-in-progress is 12% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-17 days / 2 yrsWithin range

Days payable changed by -17 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, FIIs added 1.9 pts; DIIs trimmed 0.8 pts.
  • The number of shareholders rose from 1.1 lakh to 1.3 lakh (+10%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters75.0%75.0%0.0 pts
FIIs2.9%4.8%+1.9 pts
DIIs8.6%7.8%-0.8 pts
Public and others13.4%12.4%-1.0 pts

Number of shareholders

1.3 lakhshareholders+10% since Dec '23
1.1L1.2L1.2L1.3L Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 1.1 lakh
Mar '24: 1.2 lakh
Jun '24: 1.2 lakh
Sep '24: 1.2 lakh
Dec '24: 1.2 lakh
Mar '25: 1.2 lakh
Jun '25: 1.2 lakh
Sep '25: 1.2 lakh
Dec '25: 1.2 lakh
Mar '26: 1.2 lakh
Jun '26: 1.3 lakh
 1.1L1.2L1.2L1.3L Dec '23Dec '24Dec '25Jun '26
Dec '23: 1.1 lakh
Mar '24: 1.2 lakh
Jun '24: 1.2 lakh
Sep '24: 1.2 lakh
Dec '24: 1.2 lakh
Mar '25: 1.2 lakh
Jun '25: 1.2 lakh
Sep '25: 1.2 lakh
Dec '25: 1.2 lakh
Mar '26: 1.2 lakh
Jun '26: 1.3 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−7.5%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like GLAXOSMITHKLINE PHARMACEUTICAL today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −23% to +9% vs the market, against −4% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −3.6%, 80% range −12.8% to −1.5%), but the matches cluster in only 5 distinct 12-month windows.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
PGHH · Sep 2025: −52.2% vs market
CLEAN · Feb 2025: −47.8% vs market
SANOFI · Jun 2025: −46.6% vs market
BATAINDIA · Apr 2020: −37.2% vs market
INDIAMART · Oct 2025: −36.1% vs market
IRCTC · Oct 2025: −35.9% vs market
CASTROLIND · Feb 2020: −35.0% vs market
VSTIND · Mar 2020: −32.0% vs market
SAREGAMA · May 2022: −31.2% vs market
SUMICHEM · Oct 2022: −31.0% vs market
ITC · Mar 2020: −29.2% vs market
PFIZER · Oct 2025: −25.2% vs market
EMAMILTD · Aug 2024: −23.5% vs market
ABBOTINDIA · Aug 2025: −22.0% vs market
SANOFICONR · Sep 2025: −19.9% vs market
BAJAJ-AUTO · Jul 2020: −18.7% vs market
AJANTPHARM · Sep 2024: −18.6% vs market
OFSS · May 2020: −17.5% vs market
BRITANNIA · Feb 2020: −16.8% vs market
GILLETTE · Nov 2024: −14.8% vs market
HONAUT · Sep 2020: −14.3% vs market
COHANCE · Jun 2022: −12.5% vs market
COLPAL · May 2024: −12.1% vs market
FINEORG · Jul 2020: −8.9% vs market
MARICO · Jun 2020: −7.7% vs market
ALKYLAMINE · Aug 2025: −7.2% vs market
HINDUNILVR · Jan 2020: −6.5% vs market
SCHAEFFLER · May 2024: −6.0% vs market
ATUL · Oct 2020: −4.9% vs market
CGPOWER · Jul 2024: −4.5% vs market
BEL · Jul 2025: −3.9% vs market
PGHL · Oct 2025: +0.1% vs market
PAGEIND · Apr 2020: +2.1% vs market
3MINDIA · Apr 2025: +3.7% vs market
INGERRAND · Sep 2025: +4.7% vs market
TCS · Feb 2020: +6.3% vs market
PIDILITIND · Oct 2025: +6.9% vs market
HAL · Oct 2025: +9.6% vs market
EICHERMOT · Mar 2020: +10.6% vs market
CRISIL · Nov 2020: +11.8% vs market
SUPREMEIND · Mar 2023: +13.3% vs market
CDSL · Feb 2024: +20.5% vs market
ESABINDIA · Jan 2022: +23.7% vs market
LALPATHLAB · Sep 2025: +26.7% vs market
CAMS · Nov 2023: +36.1% vs market
CUMMINSIND · Jul 2025: +47.3% vs market
THYROCARE · Jun 2020: +58.0% vs market
IEX · Feb 2021: +75.3% vs market
INOXINDIA · Aug 2025: +77.1% vs market
TATAELXSI · Feb 2020: +121.2% vs market
Similar setups −7.5%All companies −3.9%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−7.5%
All companies' median
−3.9%
Beat the market
38% vs 46%

50 past situations · 50 companies · 30 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CRISIL
Commercial Services		 Nov 2020 42x42% +24%−4% +12%
ABBOTINDIA
Health Technology		 Aug 2025 46x46% +4%−12% −22%
IRCTC
Consumer Services		 Oct 2025 43x49% −13%−16% −36%
INGERRAND
Producer Manufacturing		 Sep 2025 47x60% −5%−16% +5%
PGHH
Consumer Non-Durables		 Sep 2025 55x104% −15%−16% −52%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
3MINDIA
Producer Manufacturing		 Apr 2025 56x41% −1%−25% +4%
GILLETTE
Consumer Non-Durables		 Nov 2024 76x59% +54%−6% −15%
EICHERMOT
Consumer Durables		 Mar 2020 16x41% −36%−44% +11%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to GLAXOSMITHKLINE PHARMACEUTICAL. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

GILLETTE INDIAGILLETTE
Consumer Non-Durables
86%similar
promoter holdingROCE
HINDUSTAN AERONAUTICSHAL
Electronic Technology
71%similar
volatilityoperating margin
INGERSOLL-RAND (INDIA)INGERRAND
Producer Manufacturing
71%similar
promoter holdingdebt/equity
3M INDIA3MINDIA
Producer Manufacturing
70%similar
promoter holdingrevenue
PIDILITE INDUSTRIESPIDILITIND
Process Industries
69%similar
volatilityoperating margin
ABBOTT INDIAABBOTINDIA
Health Technology
84%similar
market capROCE
ANTHEM BIOSCIENCESANTHEM
Health Technology
63%similar
market capdebt/equity
AJANTA PHARMAAJANTPHARM
Health Technology
62%similar
market capvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '22

  1. NovPriceVolume reached 16.3x its 50-day median on 2026-11-09; price +6.7% that day.
  2. AugPriceVolume reached 16.5x its 50-day median on 2026-08-19; price +5.4% that day.
  3. JunPriceFell 38% from the Jun 2025 peak to the Jun 2026 low.
  4. JunPriceVolume reached 5.1x its 50-day median on 2026-06-12; price +0.9% that day.
  5. MarResultsRevenue (TTM) reached a new high of ₹3,800 cr.
  6. MarPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  7. DecPriceVolume reached 7.3x its 50-day median on 2025-12-30; price -3.8% that day.
  8. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
Show 22 earlier events
  1. MayPriceRegained the 2024-08 peak, 3 months after the low.
  2. AprPriceVolume reached 13.5x its 50-day median on 2025-04-24; price +2.4% that day.
  3. MarPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  4. FebPriceFell 36% from the Aug 2024 peak to the Feb 2025 low.
  5. FebPriceVolume reached 49.8x its 50-day median on 2025-02-18; price +8.4% that day.
  6. SepResultsYear-on-year EPS growth turned positive.
  7. JulPriceVolume reached 9.6x its 50-day median on 2024-07-23; price +2.6% that day.
  8. JunResultsRevenue (TTM) reached a new high of ₹3,454 cr.
  9. JunPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
  10. MayPriceVolume reached 9.6x its 50-day median on 2024-05-17; price +13.1% that day.
  11. JanPriceVolume reached 6.3x its 50-day median on 2024-01-02; price +5.0% that day.
  12. DecPriceRegained the 2021-12 peak, 7 months after the low.
  13. NovPriceVolume reached 8.2x its 50-day median on 2023-11-20; price +4.5% that day.
  14. SepPriceVolume reached 5.1x its 50-day median on 2023-09-13; price +5.6% that day.
  15. JunResultsYear-on-year EPS growth turned negative.
  16. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the top quartile).
  17. MayPriceFell 35% from the Dec 2021 peak to the May 2023 low.
  18. MayPriceVolume reached 9.0x its 50-day median on 2023-05-02; price -0.9% that day.
  19. FebPriceVolume reached 8.0x its 50-day median on 2023-02-08; price +3.1% that day.
  20. AugPriceVolume reached 10.0x its 50-day median on 2022-08-08; price +2.5% that day.
  21. JunResultsRevenue (TTM) reached a new high of ₹3,278 cr.
  22. JunValuationP/E fell below the 10th percentile of its own history to date (14.6x).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1143.0x₹3954 cr47.1%61.0%0.0x
2026-1039.6x₹3954 cr47.1%61.0%0.0x
2026-0943.9x₹3954 cr47.1%61.0%0.0x
2026-0849.9x₹3821 cr45.7%61.0%0.0x
2026-0743.4x₹3821 cr45.7%61.0%0.0x
2026-0640.1x₹3821 cr45.7%61.0%0.0x
2026-0536.7x₹3800 cr52.3%63.0%0.0x
2026-0437.8x₹3800 cr52.3%63.0%0.0x
2026-0336.9x₹3800 cr52.3%63.0%0.0x
2026-0244.5x₹3708 cr48.9%63.0%0.0x
2026-0141.5x₹3708 cr48.9%63.0%0.0x
2025-1242.8x₹3708 cr48.9%63.0%0.0x
2025-1144.7x₹3739 cr48.7%63.0%0.0x
2025-1045.5x₹3739 cr48.7%63.0%0.0x
2025-0946.2x₹3739 cr48.7%63.0%0.0x
2025-0849.6x₹3749 cr47.5%63.0%0.0x
2025-0756.3x₹3749 cr47.5%63.0%0.0x
2025-0660.3x₹3749 cr47.5%63.0%0.0x
2025-0563.4x₹3705 cr48.3%51.0%0.0x
2025-0457.0x₹3705 cr48.3%51.0%0.0x
2025-0355.4x₹3705 cr48.3%51.0%0.0x
2025-0260.6x₹3561 cr37.9%51.0%0.0x
2025-0148.4x₹3561 cr37.9%51.0%0.0x
2024-1255.1x₹3561 cr37.9%51.0%0.0x
2024-1163.1x₹3507 cr36.0%51.0%0.0x
2024-1070.0x₹3507 cr36.0%51.0%0.0x
2024-0971.0x₹3507 cr36.0%51.0%0.0x
2024-0876.9x₹3454 cr33.2%51.0%0.0x
2024-0776.5x₹3454 cr33.2%51.0%0.0x
2024-0674.2x₹3454 cr33.2%51.0%0.0x
2024-0570.9x₹3252 cr35.1%36.0%0.0x
2024-0456.4x₹3252 cr35.1%36.0%0.0x
2024-0352.7x₹3252 cr35.1%36.0%0.0x
2024-0258.8x₹3252 cr35.1%36.0%0.0x
2024-0160.9x₹3252 cr35.1%36.0%0.0x
2023-1251.3x₹3252 cr35.1%36.0%0.0x
2023-1144.8x₹3252 cr35.1%36.0%0.0x
2023-1038.5x₹3252 cr35.1%36.0%0.0x
2023-0941.9x₹3252 cr35.1%36.0%0.0x
2023-0838.7x₹3252 cr35.1%36.0%0.0x
2023-0737.8x₹3252 cr35.1%36.0%0.0x
2023-0638.5x₹3252 cr35.1%36.0%0.0x
2023-0512.7x₹3278 cr63.6%37.0%0.0x
2023-0412.1x₹3278 cr63.6%37.0%0.0x
2023-0312.9x₹3278 cr63.6%37.0%0.0x
2023-0213.0x₹3278 cr63.6%37.0%0.0x
2023-0112.1x₹3278 cr63.6%37.0%0.0x
2022-1212.9x₹3278 cr63.6%37.0%0.0x
2022-1113.0x₹3278 cr63.6%37.0%0.0x
2022-1013.4x₹3278 cr63.6%37.0%0.0x
2022-0913.9x₹3278 cr63.6%37.0%0.0x
2022-0814.2x₹3278 cr63.6%37.0%0.0x
2022-0713.7x₹3278 cr63.6%37.0%0.0x
2022-0614.6x₹3278 cr63.6%37.0%0.0x
2022-0569.7x₹2926 cr24.2%38.0%0.0x
2022-0472.5x₹2926 cr24.2%38.0%0.0x
2022-0376.9x₹2926 cr24.2%38.0%0.0x
2022-0270.1x₹2926 cr24.2%38.0%0.0x
2022-0172.1x₹2926 cr24.2%38.0%0.0x
2021-1281.0x₹2926 cr24.2%38.0%0.0x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback